jansucko / iStockphoto.com
29 June 2018Europe
Advent agrees to buy Sanofi’s European generics unit
Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018 France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.
Editor's picks
Editor's picks
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018 France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.
Europe
19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018 France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.